相关实验视频
Updated: Jun 12, 2025
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
12.8K
心脏病的基因疗法:方法,挑战和未来的方向
Luca Grisorio1, Rossana Bongianino2, Matteo Gianeselli3
1Department of Internal Medicine, University of Pavia, Via Golgi 19, Pavia, 27100, Italy.
Cardiovascular research
|September 20, 2024
概括
心脏基因疗法正在进步,为遗传性心脏病提供了新的希望. 本综述探讨了遗传性心脏病的分子方法和传递载体.
科学领域:
- 心血管医学 心血管医学
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 基因疗法正在迅速发展,最近的临床试验成功提升了科学信心.
- 心脏基因治疗领域现在正在加速,解决治疗遗传性心脏病的挑战.
- 由于明确的分子机制和遗传干预的潜力,单一性心脏病是主要的目标.
研究的目的:
- 审查心脏基因治疗遗传性心脏疾病的最新进展.
- 讨论各种分子策略和输送载体,评估它们的治疗潜力和局限性.
- 确定影响心脏基因治疗临床转换的关键因素.
主要方法:
- 关于心脏基因疗法的最新进展的文献综述.
- 分析不同的分子方法和输送矢量.
- 检查临床试验数据和遗传性心脏病的前景.
主要成果:
- 心脏基因治疗正在克服生物学和技术上的障碍.
- 单一性心脏病代表着一个重要的"基因可用药"领域.
- 目前针对这些疾病的治疗方法有限,这凸显了对新型治疗策略的需求.
结论:
- 心脏基因疗法在治疗遗传性心脏病方面显示出显著的前景.
- 仔细考虑分子方法,传递载体和临床转化因子至关重要.
- 持续的研究和开发对于实现基因治疗在心脏病学中的全部治疗潜力至关重要.
相关概念视频
00:59Gene Therapy
25.3K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.3K
01:26Heart Failure Drugs: Inotropic Agents
539
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
539